Immunotherapy is still experimental and is given either alone or in combination with chemotherapy and/or radiation.Ī multi-disciplinary approach is paramount to achieving optimal outcomes for MIBC patients, irrespective of their age, performance and nutritional status, fitness/frailty, renal and other organ function, or disease severity.Īdjuvant chemotherapy Bladder-sparing Chemoradiation Enhanced recovery after surgery Muscle-invasive bladder cancer Neoadjuvant chemotherapy Radical cystectomy Transurethral resection of bladder tumor Trimodal Urothelial carcinoma of bladder Variant histology.Southern ringneck snake, Diadophis p. Trimodal bladder-preserving treatment via maximum transurethral resection of bladder tumor followed by concurrent chemoradiation is safe and, when combined with early salvage RC for recurrence, offers long-term survival rates in selected patients comparable to RC. Adjuvant (Adj) cisplatin-based combination chemotherapy may be considered, particularly for pT3-4 and/or pN+ disease without prior NA chemotherapy. Neoadjuvant (NA) cisplatin-based combination chemotherapy improves overall survival and should be offered to eligible ≥ cT2N0 patients. While associated with substantial morbidity and mortality, this has been mitigated with improved technique, minimally invasive technology, and better perioperative care pathways (e.g., enhanced recovery after surgery). Radical cystectomy (RC) is the standard of care for MIBC patients considered to be surgical candidates. An international multi-disciplinary expert panel evaluated and graded the data according to guidelines from the Oxford Centre for Evidence-Based Medicine. provide a comprehensive overview and update of the Joint Société Internationale d'Urologie-International Consultation on Urological Diseases (SIU-ICUD) Consultation on Bladder Cancer for muscle-invasive presumably node-negative bladder cancer (MIBC).Ĭontemporary literature was analyzed for the latest evidence in treatment options, outcomes, including radical surgery, neoadjuvant and adjuvant treatment modalities, and bladder-sparing approaches. 16 Department of Urology, University of Tübingen, Tübingen, Germany. 15 PSMAR-IMIM Hospital del Mar Medical Research Institute, Barcelona, Spain. 14 Genitourinary Division, Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.1 Department of Urology, Tan Tock Seng Hospital, Singapore, Singapore. 13 Department of Urology, University of Lille Nord de France, Lille, France.12 Genitourinary Division, Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.11 Department of Urology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA.10 Department of Radiation Oncology, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC, USA.9 Department of Urology, University of Rochester Medical Center, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA.8 Department of Urology, University Hospital of Cologne, Cologne, Germany.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |